"I was fighting to survive": Patients still struggle with preauthorization despite promise of reform

Last summer, the Trump administration announced a voluntary pledge by health insurers to reform prior authorization, but patient advocates and medical providers remain skeptical.

Kedrion Activates Nationwide Distribution Network for QIVIGY® in the U.S.

Today Kedrion Biopharma announced the nationwide commercial availability of QIVIGY, its FDA‑approved 10% Intravenous ...

argenx SE: Excellent Company, Premium Valuation

SE has achieved rapid commercial success with VYVGART, driving $4.2 billion in 2025 sales and operational profitability. Learn more about ARGX stock here.
Le Lézard

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Stan…

Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG ...